Sientra to Report Second Quarter 2022 Financial Results on August 11, 2022

SANTA BARBARA, Calif., July 28, 2022 (GLOBE NEWSWIRE) — Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, today announced that it will release financial results for the second quarter of 2022 after the close of trading on Thursday, August 11, 2022. Sientra will host a conference call to discuss financial results the same day at 4:30 p.m. Eastern Time.

The dial-in numbers are 1-866-374-5140 for domestic callers. The conference ID is 32094933. The webcast link is the following: Sientra Q2′ 2022 Earnings Call Webcast Registration Link.

A live webcast of the conference call will be available on the Investor Relations section of the Company’s website at www.sientra.com. The webcast will be archived on the website following the completion of the call.

About Sientra
Headquartered in Santa Barbara, California, Sientra is a medical aesthetics company exclusively focused on plastic surgery. The Company mission is to offer proprietary innovations and unparalleled partnerships that radically advance how plastic surgeons think, work and care for their patients. Sientra has developed a broad portfolio of products with technologically differentiated characteristics, supported by independent laboratory testing and strong clinical trial outcomes. The Company’s product portfolio includes its Sientra round and shaped breast implants, the first fifth generation breast implants approved by the FDA for sale in the United States, its ground-breaking Allox2® breast tissue expander with patented dual-port and integral drain technology, the AuraGen fat grafting system, and BIOCORNEUM®, the #1 performing, preferred and recommended scar gel of plastic surgeons(*).

Sientra uses its investor relations website to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Sientra is routinely posted and is accessible on the Company’s investor relations website at www.sientra.com.

(*) Data on file

Investor Relations Contact
Aman R. Patel, CFA
aman.patel@westwicke.com

Staff

Recent Posts

Angle PLC Announces Parsortix at European Breast Cancer Conference

PARSORTIX SYSTEM AND ASSAYS BEING SHOWCASED AT A LEADING EUROPEAN BREAST CANCER CONFERENCEANGLE presenting two…

2 hours ago

MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR Act

PLANEGG and MUNICH, GERMANY / ACCESSWIRE / March 22, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today…

5 hours ago

Relief Therapeutics Enters into Exclusive U.S. License and Supply Agreement with Eton Pharmaceuticals for PKU GOLIKE

GENEVA, SWITZERLAND / ACCESSWIRE / March 22, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY )…

5 hours ago

Biophytis Presented its Phase 3 Protocol in the Treatment of Sarcopenia

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / March 22, 2024 / Biophytis SA (Nasdaq:BPTS)(Euronext…

5 hours ago

Biolase Reports Full-Year 2023 Results; Expects Continued Revenue Growth In 2024

LAKE FOREST, CA / ACCESSWIRE / March 21, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), the globally…

14 hours ago

Free Dementia Training in Alabama

Bring Dementia Education at No Cost to Your Skilled Nursing HomeTUSCALOOSA, AL / ACCESSWIRE /…

14 hours ago